Indira Poola, PhD

Founder and President
SILBIOTECH, Inc., North Potomac, Maryland, USA

Dr. Poola is the Founder and President of SILBIOTECH, Inc. SILBIOTECH specializes in discovering biological markers for precancerous breast cancer lesions, which allow physicians to make clinical treatment decisions accordingly. Before starting SILBIOTECH, Dr. Poola had been a breast cancer scientist for the past 30+ years and Senior Professor at Howard University Medical School in Washington, D.C.. She is the recipient of a few dozens of extramural awards from multiple national agencies, including National Cancer Institutes, National Science Foundation, Department of Defense, and Susan G. Komen for Cure. Over the years, Dr. Poola has extensively participated in numerous national and international peer-reviewed funding panels for breast cancer research. She is passionate about preventing breast cancer and has conducted ground-breaking research to define the biology of precancerous breast tumors and molecular changes associated with cancer progression, thereby identifying certain oncoproteins with a predictive value for breast cancer development. These discoveries have resulted in the development of a multi-marker cancer risk test, BBDRisk Dx®, for patients who have precancerous breast tumors such as atypical ductal hyperplasia, atypical lobular hyperplasia, usual ductal hyperplasia, and papilloma tumor types. Currently, the BBDRisk Dx® test is used by oncologists in the United States to assess the risk of breast cancer among women who have precancerous breast tumors.